BRIEF published on 09/18/2024 at 20:05, 1 year 9 months ago Levée de fonds de 0,25 M€ par Néovacs Investissement Biotechnologie Levée De Fonds Dilution OCEANE-BSA
PRESS RELEASE published on 09/18/2024 at 20:00, 1 year 9 months ago Levée de fonds de 0,25 MEUR Néovacs annonce une levée de fonds de 0,25 M€ via l'émission d'OCEANE-BSA pour financer la recherche sur les allergies et investir dans des projets prometteurs en Biotech et MedTech Biotech Levée De Fonds Néovacs OCEANE-BSA Recherche Allergies
BRIEF published on 08/28/2024 at 23:05, 1 year 10 months ago Adjustment of the nominal value: Neovacs reduces its capital Financial Health Euronext Growth Capital Reduction Nominal Value Néovacs
BRIEF published on 08/28/2024 at 23:05, 1 year 10 months ago Ajustement de la valeur nominale : Néovacs réduit son capital Euronext Growth Réduction De Capital Santé Financière Valeur Nominale Néovacs
PRESS RELEASE published on 08/28/2024 at 23:00, 1 year 10 months ago Ajustement de la valeur nominale Néovacs réduit la valeur nominale de son action de 0,005 € à 0,0005 € suite à une réduction de capital. La société biopharmaceutique développe des thérapies pour des maladies inflammatoires et auto-immunes Biopharmaceutique Réduction De Capital Maladies Inflammatoires Valeur Nominale Néovacs
BRIEF published on 07/04/2024 at 20:05, 2 years ago Termination of the financing contract granted to Pharnext Termination Funding Biopharmaceutical Pharnext Néovacs
BRIEF published on 07/04/2024 at 20:05, 2 years ago Résiliation du contrat de financement accordé à Pharnext Financement Biopharmaceutique Pharnext Résiliation Néovacs
PRESS RELEASE published on 07/04/2024 at 20:00, 2 years ago Résiliation du contrat de financement accordé à Pharnext Résiliation du contrat de financement entre Néovacs et Pharnext, suite à des cas de défaut. Le fiduciaire demande le remboursement anticipé de 22 M€. Détails sur les sûretés en place Financement Pharnext Résiliation Néovacs Fiduciaire
BRIEF published on 06/17/2024 at 08:05, 2 years ago Néovacs collaborates with the CNRS to develop mRNA lipid formulations Scientific Collaboration Biomedical Research Néovacs CNRS Lipid Formulations Messenger RNA
BRIEF published on 06/17/2024 at 08:05, 2 years ago Néovacs collabore avec le CNRS pour développer des formulations lipidiques ARNm Collaboration Scientifique Recherche Biomédicale Formulations Lipidiques ARN Messager Néovacs CNRS
Published on 07/03/2026 at 23:00, 1 day 9 hours ago Eagle Plains Partner Refined Energy Announces Final Results for Winter 2026 Drill Program at Dufferin West
Published on 07/03/2026 at 21:28, 1 day 11 hours ago Trifecta Gold Announces Closing of $1.66 Million Private Placement
Published on 07/03/2026 at 19:30, 1 day 13 hours ago Polaris Renewable Energy Announces Q2 2026 Investor Call Details
Published on 07/03/2026 at 13:30, 1 day 19 hours ago Nextech3D.ai Unveils Strategic AI Growth Roadmap Focused on Workforce Intelligence and Event Technology Innovation
Published on 07/04/2026 at 17:35, 15 hours 2 minutes ago Vantage Introduces 24/7 Gold CFD Trading with XAUUSD247
Published on 07/04/2026 at 11:01, 21 hours 35 minutes ago EQS-Adhoc: Continental AG: Continental AG Sells ContiTech Group Sector
Published on 07/04/2026 at 09:05, 23 hours 32 minutes ago Velo x McLaren Mastercard Formula 1® Team Relaunches Live Your Fandom to Bring Fans Closer to the Sport They Love
Published on 07/03/2026 at 19:00, 1 day 13 hours ago PATRIMOINE ET COMMERCE: BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 30 JUIN 2026
Published on 07/03/2026 at 18:55, 1 day 13 hours ago Saudia Arabia's Mabani Aljazeera Group invests in Tatu City's Jabali Towers development
Published on 07/03/2026 at 21:49, 1 day 10 hours ago Safran annonce la fin des négociations concernant le projet d'acquisition d’Exail Technologies.
Published on 07/03/2026 at 21:49, 1 day 10 hours ago Safran announces the end of negotiations regarding the contemplated acquisition of Exail Technologies.
Published on 07/03/2026 at 18:42, 1 day 13 hours ago Total number of voting rights and shares making up the share capital at June 30, 2026
Published on 07/03/2026 at 18:36, 1 day 14 hours ago Disclosure of transactions in own shares from July 1 to July 3, 2026
